#US Acute Myelogenous Market | Explore Tumblr Posts and Blogs

kenresearch1 · 10 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

pharmanucleus1 · 10 months

Text

Global Leukemia Therapeutics Market, Forecast 2027

Leukemia Therapeutics Market

Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia. Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments.

Market Size & Growth Rate:

The leukemia therapeutics market was valued at USD 13.5 billion in 2021 and is projected to reach USD 17.1 billion by 2027, with a CAGR of 7.2% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.

Click here for full report:

https://www.pharmanucleus.com/reports/leukemia-therapeutics-market

Market Dynamics:

On account of the growing number of people suffering from leukemia, the leukemia therapeutics treatment market has been driven by technological research & developments, the merging of healthcare organizations and new approvals in the field of blood cancer diagnostics across the globe.

The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)-April 2021, announced five new investments in increasing the development of new and improved immunotherapies in Abintus Bio, Nexlmmune, Caribou Biosciences and Immune-Onc Therapeutics for the treatment of leukemia cancer.

Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Additionally, the Government initiatives and programs at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2027.

Market Drivers:

The growing research and technological development activities.

Increasing product approval and product launch by the market players are expected to propel the leukemia therapeutics market, and also technological developments are likely to create various new opportunities that will impact this leukemia therapeutics market growth in the forecast period. For instance,

In May 2022, Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) received FDA approval for combination with azacitidine in newly diagnosed AML with a susceptible IDH1 mutation in adults 75 years and older.

On June 2021, Jazz Pharmaceuticals received FDA approval for a new form of Rylaze (asparaginase erwinia chrysanthemi recombinant rywn) to be developed as part of a treatment for children and adults with ALL

In October 2021, Kite Pharma received FDA approval for use of the CAR T-cell therapy brexucabtagene autoleucel developed by Tecartus (the first CAR T-cell therapy approved) in adults with B-cell precursor ALL

In November 2018, Pfizer Inc. received U.S. FDA approval for Glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from AML

Increasing incidence of leukemia to boost leukemia therapeutics market growth.

One of the foremost driving factors influencing the global market is the increasing prevalence of leukemia across the globe, according to the National Cancer Institute (NCI), approximately 1.5% of people were diagnosed with leukemia during their lifetime. Additionally, in the report-2022, the estimated number of living people with new leukemia cases will be 60,650, and the number of death cases will be 24,000 in the United States.

According to the American Cancer Society-2022, the CLL segment is anticipated 20,160 diagnosis cases including both children & adults in US leukemia therapeutic market, as CLL is the first line of treatment for it followed by AML and CML.

Click here for full report:

Get more details on this report - Request Free Sample

Substantial progress has been made against cancer in recent decades. As of 2019, the rate has declined by 32%, mostly because of advances in early detection and treatment for some cancers including leukemia. It reflects largely driven by progress against leukemia cancer.

Challenges:

The high cost of treatment and stringent regulatory scenario restrain the market growth.

High cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period. For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging.

The low diagnosis rate of leukemia & lack of proper healthcare facilities in developing countries

Adverse reactions of leukemia therapeutics

Competitive landscape:

Novartis International AG, Bristol Myers Squibb, Sanofi S.A, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Abintus Bio, Nexlmmune, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd, AbbVie, Ambit Biosciences corporation, Ariad Pharmaceuticals, Gennzme Corporation, Rpche, and Others.

Key Developments:

Get more details on this report - Request Free Sample

Regional Analysis:

North America was the largest region in the leukemia therapeutics market in recent years and it is anticipated to capture the highest share of this market over the forecast period 2022-2027, with the U.S. accounting for the maximum contribution and it has well-developed structural healthcare systems. In addition, the high prevalence of leukemia and the rising geriatric population, based on the NCI-2022 report, leukemia represents 3.2% of all new cancer cases in the U.S., and the incidence rate increased in children and adolescents by about 1% per year and was stable in adults ages 20 and older. The presence significant of key players, some of the best research universities, and encouraging new product developments & launches for research lead to more significant assets in the pipeline. For instance,

In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?

In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to enhance its oncology portfolio with the addition of next-generation immune therapies.

#Leukemia Therapeutics Market #leukemia care #global therapeutics market #innovative treatments #groundbreaking developments

0 notes

medchemexpressinhibitor-blog · 2 years

Text

Antibody — Drug Conjugates (ADCs), a Growing Class of Targeted Cancer Therapeutics

Despite of disappointing clinical results and withdraw for the first antibody-drug conjugate (ADC) Gemtuzumab ozogamicin, tremendous ADC development on modification and optimization has been attempted to improve clinical efficacy and minimize toxicity. After decades of dynamic research, these efforts are now bearing fruit with about a dozen of new ADC approvals in the past 10 years (Table 1). In 2017, a lower and fractionated dose of Gemtuzumab ozogamicin was approved too. Most recently, the phenomenal clinical results of Trastuzumab deruxtecan used in the treatment of previously treated HER2-low advanced breast cancer ignite more enthusiasm in the field and will certainly boost exponential research and growth in the development of ADCs for more approvals.DrugMakerIndicationsTrade nameTarget AntigenApproval Year

Gemtuzumab ozogamicinPfizer/WyethRelapsed acute myelogenous leukemia (AML)MylotargCD332017;2000

Brentuximab vedotinSeattle Genetics, Millennium/TakedaRelapsed HL and relapsed sALCLAdcetrisCD302011

Trastuzumab emtansineGenentech, RocheHER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoidKadcylaHER22013

Inotuzumab ozogamicinPfizer/WyethRelapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemiaBesponsaCD222017

Moxetumomab pasudotoxAstrazenecaAdults with relapsed or refractory hairy cell leukemia (HCL)LumoxitiCD222018

Polatuzumab vedotin-piiqGenentech, RocheRelapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)PolivyCD792019

Enfortumab vedotinAstellas/Seattle GeneticsAdult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapyPadcevNectin-42019

Trastuzumab deruxtecanAstraZeneca/Daiichi SankyoAdult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimensEnhertuHER22019

Sacituzumab govitecanImmunomedicsAdult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic diseaseTrodelvyTrop-22020

Belantamab mafodotin-blmfGlaxoSmithKline (GSK)Adult patients with relapsed or refractory multiple myelomaBlenrepBCMA2020

Loncastuximab tesirine-lpylADC TherapeuticsLarge B-cell lymphomaZynlontaCD192021

Tisotumab vedotin-tftvSeagen IncRecurrent or metastatic cervical cancerTivdakTissue factor2021

Table 1. FDA-approved ADC drugs

The concept of ADC can be traced back to the early 1900s, when German physician and scientist Paul Ehrlich proposed a visionary “magic bullet” that could deliver a toxic drug to certain malignant cells without affecting other normal tissues.

In the second half of last century, advances in chemistry for the linkage between cytotoxic agents and antibodies, as well as new techniques in hybridoma technology enabling the production of homogenous and target-accurate mAbs, led to the generation of ADCs with promising results. Now at a seemingly golden age of ADC drug development, the global market sales for ADC drugs are projected to exceed $ 16.4 billion in the next five years.[1] A scheme of the brief history of ADC development is shown in Fig 1 and the structures of some selected FDA-approved ADCs are listed in Fig 2.

Figure 1. Brief History of ADC development

[2]

Figure 2. Structures of selected FDA-approved ADCs

[3]

(Orange: cytotoxin agents; blue: linkers; purple: antibodies)Structure and Mechanism of Action of ADC

Different from traditional chemotherapeutics, all ADCs consist of three core components: a monoclonal antibody that can binds to a tumor-associated antigen, a cytotoxic agent (payload) and a cleavable or uncleavable linker that covalently connects antibody and payload. After ADC enters blood circulation system, the antibody component of ADC recognizes and binds to the cell-surface antigens on the targeted cancer cells. Upon internalization of the ADC-antigen complex through endocytosis, payload component is released into cytosol after cleavage by lysosome degradation pathway. The released bioactive payload binds to its targets, resulting in cancer cell death. [4]

The targeted delivery cytotoxic payload by ADC is expected to increase payload concentration in tumor cells, thus minimizing the required effective dose. The therapeutic window is narrow for early ADCs due to their off-target toxicity linked to unstable conjugation, competition with unconjugated antibody, and aggregation or fast clearance of conjugates. Although the basic approach of design and construction of ADCs remain constant, the selection of three components significantly affects the pharmacokinetic, pharmacodynamic, and clinical outcomes among different ADCs.

The latest developments in new payload discovery, linker optimization, antibody engineering, and advances of conjugation chemistry have led to the third generation of ADCs with improved therapeutic window (Fig 3).

Figure 3. Therapeutic window of ADCs

[5]

Target Antigen Selection

The features of an ideal target antigen includes: 1) Predominantly expressed on the surface of target tumor cells with limited heterogeneity compared to normal tissues; 2) Minimal antigen shedding to avoid antibody binding within the circulation; 3) Well internalizing ADC through receptor-mediated endocytosis and should not be modulated during endocytosis; 4) Antigen levels remain constant after ADC treatment.

Target antigens in stroma and vasculature in solid tumor is another approach. Additionally, targeting antigens in cancer stem cells has also been investigated.

Figure 4. Target antigens for ADCs in solid tumors

[6]

Selection of AntibodiesThe antibody component of ADC functions as a vehicle, responsible for selectively delivering the cytotoxic payload to the target cancer cells.

Ideal antibodies have high specificity and affinity to tumor associated antigens, good stability, low immunogenicity, low cross reaction, long circulating half-life, and efficient internalization

. Currently, human IgG isotypes, particularly IgG1, are predominantly used as antibody backbone in the construction of ADCs. Four subtypes of human IgG differ in their constant domains and hinge regions with different solubility and half-life as well as their different affinity for Fcγ receptors (FcγR) expressed on immune effector cells (Fig 5).

Figure 5. Summary of IgG subtypes for potential use in ADCs

[3]

Selection of Payloads

Studies have shown that only a small fraction of cytotoxic payload with about 1-2% of administered dose can reach the tumor cells. Therefore, high potency of cytotoxic payloads is required to achieve therapeutic efficacy, with IC50 in sub-nanomolar or picomolar range (Fig 6). Payloads are normally small molecules and exert their activity by binding to intracellular targets (Fig 7).

Other favorable features of desired payloads include acceptable aqueous solubility, sufficient stability as conjugates, low immunogenicity, and a long half-life. The payload should retain its potency when modified for linkage. In addition to prevention of antibody aggregation and clearance, a balanced hydrophobic/hydrophilic physicochemical property of payload could lead to bystander effects on killing surrounding cells.

Figure 6. Potency of selected payloads

[7]

Figure 7. Payloads for ADC drugs

[8]

Selection of ADC Linkers

The linkers covalently tethering antibody and payload moieties play critical roles in the control of pharmacokinetic and pharmacodynamic (PK/PD) properties, therapeutic window, and ultimately the efficacy of ADC. The linkers should be metabolically stable in blood, thus preventing premature cleavage and ensuring sufficient delivery of ADC to the target tumor cells. Furthermore, a desired linker is able to facilitate rapid release of free and cytotoxic payload after internalization of ADC inside the tumor cells. The linkers with calibrated hydrophobicity possess capabilities to induce bystander effects for ADC to kill additional tumor cells in vicinity, irrespective of the expression of the target antigens on their surface. Therefore, linkers consist of three moieties: a suitable functional group for conjugating to the antibody, a spacer unit containing hydrophilic elements, and a trigger for releasing the cytotoxic payload.

There are two types of linkers: cleavable and non-cleavable. Cleavable linkers can be divided into acid cleavable, reducible and protease cleavable. The most frequently used linkers are maleimidocaproyl (MC), N-succinimidyl 4-(maleimidomethyl) cyclohexane-1-carboxylate (SMCC), N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio) pentanoate (SPP), peptides, hydrazones, and disulfides.

Figure 8. Comparison of different linkers

[9]

Figure 9. Cleavage of linkers

[8]

Conjugation for ADC Construction

The stoichiometry of the linker-payloads on the antibody (drug-to-antibody ratio, DAR) is an important factor for the efficacy and safety profile of the ADC. Since most payloads are hydrophobic species. High DAR with too many payloads attached to the antibody will cause an increase in protein aggregation, ADC clearance in blood, and off-target side effects. A controlled and homogenous DAR should be optimized with maximized PK/PD profile, safety, and efficacy. Novel approaches using site-specific conjugation (SSC) aim to minimize heterogeneity and produce more homogenous ADCs, thus expanding therapeutic window. These controlled conjugation strategies include engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases.

Selection of the attachment site of linker-payload to the antibody is also crucial. The selected site should not interfere antibody-antigen binding and leave internalization process unaffected. Additionally, the attachment site could have an impact on linker stability, subsequently affecting drug release rate.

Figure 10. The therapeutic effects of DAR and attachment sites on ADCs

[3]

Summary and ProspectiveA widespread interest in the development of ADC drugs for targeted cancer treatment in the past decade has led to a dozen of FDA-approved ADC drugs. Extensive research on selection of antigen targets and payloads, antibody engineering, linker optimization, and conjugation chemistry enable the construction of homogenous, effective, and safe ADCs with wider therapeutic windows. The rapid growth of ADC development warrants more innovative ADCs in the near future.Strength of MCE ServicesWe have extensive experiences in research and development of ADC products. Having strong technical teams and state-of-the-art instruments, MCE is proud to partner with clients including academic research laboratories and international pharmaceutical companies, such as Abbie and AstraZeneca. Efficient and prompt services with high-quality products are guaranteed.

Wide-Range of Diversified ProductsWith breakthroughs and innovations on payload synthesis, diversified linkers, and conjugation chemistry, we offer customer synthesis of the most comprehensive, integrated portfolio of ADC products in response to clients’ needs. MCE serves global customers with 1000+ ADC related products.

One-stop Services for ADCsWith strong teams of experienced biochemists, synthetic and analytical chemists, MCE can provide one-stop services for the design, synthesis, analysis, purification, optimization, detection, and evaluation of ADC-related products (antibodies, payloads, linkers, drug-linker conjugates, and ADC drugs).

Related ProductsProduct NameDescription

ADC Cytotoxin

Mertansine (DM1)

A microtubulin maytansinoid inhibitor. To overcome systemic toxicity and enhance tumor-specic delivery.

Calicheamicin

An antitumor antibiotic. A DNA synthesis inhibitor. To cause double-strand DNA breaks.

ADC Linker

MC-Val-Cit-PAB

A cathepsin cleavable ADC linker that is used for making antibody-drug conjugate.

SMCC

A non-cleavable ADC linker that is used for making antibody-drug conjugate.

Drug-Linker Conjugates for ADC

SMCC-DM1 (DM1-SMCC)

SMCC-DM1 (DM1-SMCC) is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and an SMCC linker to make antibody drug conjugate (ADC).

MC-Val-Cit-PAB-duocarmycin

MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity using Duocarmycin (a DNA minor groove binding alkylating agent), connected via the ADC linker MC-Val-Cit-PAB.

Antibody-drug Conjugates (ADCs)

Trastuzumab emtansine

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab deruxtecan

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. References

References[1]. do Pazo C, Nawaz K, Webster RM, et al. The oncology market for antibody-drug conjugates. Nat Rev Drug Discov. 2021 Aug;20(8):583-584.

[2]. David E Thurston, Paul J M Jackson, et al. Cytotoxic Payloads for Antibody–Drug Conjugates[M]. The Royal Society of Chemistry, 2019.

[3]. Walsh SJ, Bargh JD, Dannheim FM, Hanby AR, Seki H, Counsell AJ, Ou X, Fowler E, Ashman N, Takada Y, Isidro-Llobet A, Parker JS, Carroll JS, Spring DR. Site-selective modification strategies in antibody-drug conjugates. Chem Soc Rev. 2021 Jan 21;50(2):1305-1353.

[4]. Chau CH, Steeg PS, Figg WD, et al. Antibody-drug conjugates for cancer. Lancet. 2019 Aug 31;394(10200):793-804.

[5]. Beck A, Goetsch L, Dumontet C, Corvaïa N, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

[6]. Diamantis N, Banerji U, et al. Antibody-drug conjugates--an emerging class of cancer treatment. Br J Cancer. 2016 Feb 16;114(4):362-7.

[7]. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T, et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185.

[8]. Drago JZ, Modi S, Chandarlapaty S, et al. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021 Jun;18(6):327-344.

[9]. Tsuchikama K, An Z, et al. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018 Jan;9(1):33-46.

0 notes

bhandvalkar94 · 3 years

Text

Global Stem Cell Banking Market Analysis, Key Company Profiles, Types, Applications and Forecast to 2030

Absolute Markets Insights announced the addition of a statistical data titled as, Stem Cell Banking Market to its massive repository. Additionally, it offers extensive research on different dynamic aspects of the businesses to understand the impact of those. Primary and secondary research techniques have been used by analysts for studies data effectively.

The global stem cell banking market is anticipated to reach US$ 15089.64 Mn by 2030 growing at a CAGR of 10% during the forecast period (2021-2030).

Different top key players such as CBR Systems, Inc., Cell Care, CHA Biotech, CordBank New Zealand, Cordlife, Cryo-Cell, CryoHoldco, Cryoviva India, CSG-BIO, Global Cord Blood Corporation., LifeCell International Pvt. Ltd., ReeLabs Pvt. Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Stem Med Pte Ltd, StemCyte, ViaCord and Vita 34 Inc. give the comparative analysis of demand supply chain. In addition to this, it highlights the historical developments, recent trends, and predictions about the future growth of the Stem Cell Banking market.

For more information about this report visit: https://www.absolutemarketsinsights.com/reports/Stem-Cell-Banking-Market-2021---2029-860

Umbilical cord accounted for the largest source in the global stem cell banking market in 2020. Cord blood stem cells can be used in therapies and transplants to treat over 85 ailments that include anaemias (different types), bone marrow cancer, leukaemias (different types), and lymphomas. More than 5,000 clinical trials are using stem cell therapies today.

In the context of medical condition, higher market share in the global stem cell banking market was held by cancer (leukaemias, lymphomas, etc.) in 2020. Stem cells can be used for the treatment of different types of cancer such as acute biphenotypic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, acute undifferentiated leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, juvenile myelomonocytic leukemia, and juvenile chronic myelogenous leukemia. In regenerative medicine, the use of stem cells has been in vogue for a long time. It is very common in the field of dermatology.

Global Stem Cell Banking Market: Report Scope

By Service Type

Storage

Testing and Processing

Collection

By Source

Umbilical Cord

Placenta

Amniotic Fluid

Bone Marrow

Others

By Medical Condition

Cancer (Leukaemias, Lymphomas, Etc.)

Non-Malignant Blood Disorders (Anaemias, Hereditary Bone Marrow Failure Syndromes, Etc.)

Immune Disorder (Severe Combined Immune Deficiency (SCID), Inherited Immune System Disorders, etc.)

Metabolic Disorders (Leukodystrophy Disorders, Mucopolysaccharidosis (MPS) Storage Diseases, Etc.)

Others

By Application

Disease Treatment & Tissue Regeneration

Clinical Research

Personalized Banking Applications

By Region

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Company: Absolute Markets Insights Email Id: [email protected] Phone: IN +91-740-024-2424 , US +1-510-420-1213 Contact Name: Shreyas Tanna Website: www.absolutemarketsinsights.com/

0 notes

zaras2424 · 3 years

Text

Oncology Pharmaceuticals Market Scenario Highlighting Major Drivers & Trends 2021-2030

Oncology Pharmaceuticals Market to Grow at 11.9% CAGR during 2021-2030, Owing to the Increasing Investments towards Holistic Development of Healthcare Infrastructure, Reports Absolute Markets Insights. Oncology is defined as study of different types of tumors and cancers such as brain tumor, blood cancer, along with its types such as anemia, hemophilia, leukemia, lymphomas, thalassemias, and cancer of other organs, with the intention of finding an effective cure and means of treatment of a particular cancer type. According to the statistical estimates published by the National Cancer Institute, about 1.9 million individuals are expected to be diagnosed with Cancer in the United States in 2021. A notable increase in death rate among patients with lung and bronchus cancer is projected to be the highest in the country in 2021.

Access the Full Report @ https://www.industryglobalnews24.com/oncology-pharmaceuticals-market-to-grow-at-119-cagr-during-20212029

The major factor driving the global oncology pharmaceuticals market is the growing incidences of hematological cancer. Hematological cancer is another name for blood cancer. Hematological cancer starts in the bone marrow of patient. According to World Health Organizations (WHO), blood cancer is responsible for about 720,000 deaths annually on a global scale, which is 7% of the total cancer deaths. In a human body, bone marrow is located at the place where blood is produced. Oncology pharmaceuticals are required for the treatment of leukemia and myeloma which are two most common forms of blood cancer. Rapid production of abnormal white blood cells causes leukemia where abnormal white blood cells cannot fight infections properly. Four types of leukemia are acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML).

Increasing investments towards holistic development of healthcare infrastructure, which caters to multitude aspects of cancer treatment, including drug therapies and other treatments options such as radiation therapy, surgery, and chemotherapy amongst others is anticipated to supplement the growth of the global oncology pharmaceuticals market over the forecast period. The rapid spread of the Covid-19 pandemic has aggravated concerns among cancer patients. It has been observed that cancer increases the risk of acute illness from Covid-19 among patients. Cancer treatments are likely to weaken the immune system and further lead to lung problems.

Key Findings of the Report:

The global oncology pharmaceuticals market and is anticipated to reach US$ 439.87 Bn by 2029 growing at a CAGR of 11.9% during the forecast period (2021-2029)

Blood cancers accounts for one tenth of the total number of all known types of cancers in this world. With early diagnosis of blood cancer being possible in technologically advanced regions, the number of people seeking treatment and receiving treatment has increased rapidly.

In 2020, the targeted therapy segment in the global oncology pharmaceuticals market held the largest market share because of several beneficial factors associated with the treatment. The advantages of targeted therapy include helping the immune system destroy cancer cells, halting cancer cells growth, delivering cell-killing substances to cancer cells, killing cancer cells, and ensuring starvation of cancer regarding hormones, which it (cancer) needs to grow.

In 2020, North America was the biggest regional market in the global oncology pharmaceuticals market due to the availability of mediums and facilities required for various advanced medical researches that could be carried out in the medical institutions. Developed medical sector, presence of key market players, technological advancement supporting the medical research, increasing number of people seeking treatment for blood cancer, and incentives offered by governments to encourage higher investment in medical research are some other factors that are contributing to the region’s growth in the global market.

Some of the major players operating in the global oncology pharmaceuticals market are Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited, amongst others.

Global Oncology Pharmaceuticals Market:

By Indication

Blood Cancer

Breast Cancer

Prostate Cancer

Basal Cell Cancer

Skin Cancer

Colorectal Cancer

Lung Cancer

Renal Cancer

Bladder Cancer

Lymphoma

Others

By Application

Drug Therapies

Antimetabolites

Antitumor Antibiotics

Asparagine-Specific Enzymes

Bisphosphonates and Biosimilars

DNA Damaging Agents and Alkylating Agents

Inhibitors

Monoclonal Antibodies

Others

Radiation Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

Hormone Therapy

Stem Cell Transplant

Others

By Route of Administration

Oral

Intravenous

Subcutaneous

Intrathecal

Intraventricular

Others

By Dosage (mg)

50 to 100

200

500

Others

By Region:

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Company: Absolute Markets Insights Email Id: [email protected] Phone: IN +91-740-024-2424 , US +1-510-420-1213 Contact Name: Shreyas Tanna Website: www.absolutemarketsinsights.com

0 notes

wiseguyreport1222 · 3 years

Link

0 notes

marketinformation · 3 years

Text

Hematologic Malignancies Market 2021: CAGR of 10.68% With Top Countries Data, Latest Trends, Market Size, share, Global Industry Analysis and Forecast by 2027

"Hematologic Malignancies Market is valued at USD 43929.55 Million in 2018 and expected to reach USD 89380.09 Million by 2025 with the CAGR of 10.68% over the forecast period."

Rising incidence of blood cancer driving the growth of hematologic malignancies market.

Scope of the Hematologic Malignancies Market Report:

Hematological malignancies are the kinds of cancer affecting blood, bone marrow and lymph nodes. It is also called as hematological disease. The many distinct sorts of mature blood cells, like red blood cells for carrying oxygen, white blood cells for immune protection and platelets for wound clotting. It is arise from hematopoietic stem and progenitor cells in the bone marrow.

Continue …. @ https://brandessenceresearch.com/healthcare/global-hematologic-malignancies-market-size

Hematologic malignancies are cancers that begin in these cells, and are subdivided according to which type of blood cell is affected such as Lymphoblastic or lymphocytic and Myelogenous or myeloid . A malignancy in the lymphoid lineage that includes white blood cells such as T lymphocytes and B lymphocytes.

For examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas and multiple myeloma. And, malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells such as granulocytes. For examples, acute myelogenous leukemia and chronic myelogenous leukemia.

Hematologic malignancies Companies:

Hematologic malignancies market report covers prominent playersare,

Pfizer Inc

F. Hoffmann-LA Roche Ltd

Sanofi

Bristol-Myers Squibb Company

AbbVieInc

Novartis AG

GlaxoSmithKline PLC

Celgene Corporation Johnson & Johnson Services, Inc

Takeda Pharmaceutical Company

Others.

Hematologic malignancies are cancers that begin in these cells, and are subdivided according to which type of blood cell is affected such as my elogenous or myeloid. A malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells such as granulocytes. The most commonly diagnosed blood cancers are non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia and multiple myeloma.

Get Free Sample PDF Copy of Latest Research on Hematologic Malignancies Market 2021 before the purchase @ https://brandessenceresearch.com/requestSample/PostId/1023?utm_source=AR

Hematologic malignancies market report is segmented on the basis of type, therapy and by regional & country level. Based upon type, Hematologic malignancies market is classified into Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma and Others. Based upon therapy, Hematologic malignancies market is classified into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation and Others.

Hematologic malignancies Market Segmentation –

By Type: - Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma, Multiple Myeloma, Others

By Therapy: - Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others

By Regional & Country Analysis:

North America

o U.S.

o Canada

U.K.

France

Germany

Italy

China

Japan

India

Southeast Asia

Brazil

Mexico

GCC

Africa

Rest of Middle East and Africa

About Brandessence Market Research Inc.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Alan Ruffalo

Corporate Sales: +44-2038074155

Email: [email protected]

Web: https://brandessenceresearch.com/

#Size #Share #trend #demand

0 notes

sapanas · 4 years

Text

Leukemia Therapeutics Market 2020: Company Profiles, Industry Segments, Size, Landscape, Demand and Business Trends

Market Research Future published a half-Cooked research report on “Global Leukemia Therapeutics Market Research Report, forecast to 2023” – Market Size, Share, Growth, Analysis, Regional Outlook, Scope, Stake, Progress, Trends.

Leukemia Therapeutics Market Overview

Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.

Read more news on: https://www.medgadget.com/2020/08/leukemia-therapeutics-market-to-grow-at-a-cagr-of-5-3-by-2023-covid-19-impact-analysis-top-comapnies-pfizer-inc-glaxosmithkline-plc-novartis-ag-bristol-myers-squibb-company-sanofi-s-a.html

Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).

The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.

On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.

Leukemia Therapeutics Market - Segments

The Leukemia Therapeutics Market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.

Leukemia Therapeutics Market - Regional Analysis

North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.

Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.

Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.

The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.

Leukemia Therapeutics Market - Competitive Analysis

The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.

Leukemia Therapeutics Market Major Players:

Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Leukemia Therapeutics Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

#Leukemia Therapeutics Market #Leukemia Therapeutics Market Size #Leukemia Therapeutics Market Share #Leukemia Therapeutics Market Growth #Leukemia Therapeutics Market Analysis #Leukemia Therapeutics Market Trends

0 notes

aditi3019 · 4 years

Text

Global Leukemia Therapeutics Market 2019 - 2023: Emerging Technologies, Business Trends, Industry Segments, Global Segments, Landscape and Demand

Global Leukemia Therapeutics Market Report, Forecast Period 2023-2020. The Industry Research Report on Global Leukemia Therapeutics Market is based on Industry Size, Share, Trend and Growth.

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/7425

Global Leukemia Therapeutics Market - Segments       

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

Global Leukemia Therapeutics Market - Regional Analysis

Global Leukemia Therapeutics Market - Competitive Analysis

Major Players:

Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). 

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

0 notes

kenresearch1 · 11 months

Text

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

0 notes

ratiram · 5 years

Link

According to the report analysis, ‘Global Hydroxycarbamide Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024’ states that there are there are numerous key players which effectively functioning in the hydroxycarbanmide market for leading the highest market growth and dominating the high value of market share across the globe in the coming years while delivering the better consumer satisfaction and developing the working techniques includesBristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, ZydusCadila, United Biotech, Par Pharma, Khandelwal Laboratories, Alkem (Cytomed), Samarth Pharma, VHB Life Sciences and several others. Moreover, this also deliver the effective information related to the profit margins, profile of the players, consequences, benefits, growth opportunities, growth drivers, applications and market analysis by the region.

The Hydroxycarbamide is also well known as Hydroxyurea, is a medication utilized in the chronic myelogenous leukemia, sickle-cell disease, cervical cancer and polycythemia vera. However, in the sickle-cell disease it augments the hemoglobin and depletes the number of attacks. It is taken by the mouth.

In 1967, the hydroxycarbamide was permitted for the medical use in the United States. It is accessible as a generic medication. Moreover, it is on the World Health Organization’s List of Essential Medicines, many efficient and safe medicines required in a health system. Furthermore, the hydroxycarnamide has been utilized generally for the cure of the myeloproliferative diseases, which has a characteristic perils of shifting to acute myeloid leukemia. The potential players of the hydroxycarbamide are playing an effective role for in decreasing the side-effects and increasing the demand of this.

Furthermore, the large enterprises in this market are implementing the profitable approaches for enlarging the business premises across the globe and investing the effective amount for deliver in the better consumer satisfaction and increasing the requirement for this around the globe during the short span of time.

Nonetheless, the cataloguing of the Hydroxycarbamideinvolves the capsule and tablet, and the proportion of capsule in 2016 is nearby 63%, and the quantity is in diminishing trend from 2012 to 2016.Whereas, the Hydroxycarbamide is extensively utilized for the sickle cell disease, cancer and several other disease. The major proportion of the Hydroxycarbamide is effectively utilized for the sickle cell disease, and the proportion in 2016 is 45%.

Based on the region, the market of hydroxycarbamide is spread across the globe which majorly includes North America, Europe and Asia-Pacific, South America, Middle East and Africa. However, owing to the significant advancement in the technologies the industrialized regions dominate the market.

For instance, the Asia Pacific is the principal purveyor of the Hydroxycarbamide, with a manufacture market share approximately 59% in 2016.

The Middle East and Africa is the principal consumption place, with a consumption market share practically 36% in 2016. Following Middle East and Africa, Asia Pacific is the second foremost consumption residence with the consumption market share of 20%.

The Market competition is not penetrating. The Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, ZydusCadila, United Biotech, Par Pharma, etc. are the foremost leaders of the industry, and they hold the key technologies and patents, with high-end consumers; have been designed in the monopoly situation in the industry. Therefore, in the near future, it is anticipated that the market of hydroxycarbamide will increase across the globe more significantly over the decades.

For more information on the research report, refer to below link:

Global Hydroxycarbamide Market 2019

Related reports

Global Hydroxycarbamide Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Global Hydroxycarbamide Market Status and Future Forecast 2015-2024

Ken Research

Ankur Gupta, Head Marketing & Communications

[email protected]

+91-9015378249

#세계적인 hydroxycarbamide 시장 조사

0 notes

healthcare00897 · 5 years

Text

Antibody Drug Conjugates Market: Shows Increasing Demand To Be Observed In The Coming Decade

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.

Get Exclusive Sample Report at: http://bit.ly/2RPnqbV

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020

The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates

Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Request For Customization of Research Report @ http://bit.ly/2FJ0bLT

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

#Antibody Drug Conjugates MarketAntibody Drug Conjugates trendsAntibody Drug Conjugates growthAntibody Drug Conjugates insights

0 notes

martynnx-blog · 5 years

Text

Antibody Drug Conjugates Market Precise Analysis and Forecast Assumptions till 2026

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/181

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

#Antibody Drug Conjugates Market #Antibody Drug Conjugates #Antibody Drug Conjugates Market 2026

0 notes

pharmaphorumuk · 5 years

Text

Mustang Bio’s first-of-a-kind CAR-T starts trials

US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the first to target CS1 protein – has started recruiting patients.

The multiple myeloma pipeline is filled with CAR-T therapies but most are targeting BCMA, including Celgene’s bb2121 which is considered the pacesetter in the race for approval in the category with an FDA verdict due later this year.

Mustang reckons that by targeting CS1 – also known as CD319, CRACC and SLAMF7 – its MB-104 CAR-T will be differentiated from the BCMA pack and could carve out a lucrative niche in the large and growing multiple myeloma market.

CS1 is expressed by cancer cells in nearly all multiple myeloma patients, and also has low expression in normal tissues, preventing those cells from being severely damaged during treatment.

The trial will be carried out at City of Hope cancer treatment and research centre in Southern California, which is fast becoming one of the premier facilities in the US for cell therapies. It will enrol heavily pre-treated myeloma patients who have received at least three prior treatment options and test positive for the CS1 antigen.

“Multiple myeloma accounts for 10% of all blood and bone marrow cancers,” said Xiuli Wang, a City of Hope research professor who has been involved in testing MB-104 in preclinical and translational research.

“CS1 is a very promising target for multiple myeloma patients who currently have few viable treatment options,” she added.

There is a precedent for the therapy as CS1 is targeted by Bristol-Myers Squibb and AbbVie’s multiple myeloma antibody Empliciti (elotuzumab), which has been tipped to become a blockbuster product but has been sluggish in its sales growth since reaching the market in 2015. Last year BMS, which books sales for the product, said it made $247 million in Empliciti revenues.

Mustang also announced this week that it had raised $32 million in a public offering that will help it fund its CAR-Ts for blood cancer, solid tumours and rare genetic diseases.

Along with MB-104. Mustang’s cancer-targeted CAR-T’s include MB-102, a CD123-targeting therapy for acute myelogenous leukaemia that is also partnered with City of Hope and due to start trials shortly, and MB-106, a CD20-targeted therapy partnered with Fred Hutchinson Cancer Center and heading towards trials in non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Its most advanced project is MB-107, a gene therapy licensed from St Jude Children’s Research Hospital for X-linked severe combined immunodeficiency (X-SCID), also called ‘bubble boy’ syndrome, that is in a phase 1/2 trial. Data from the trial were published in the New England Journal of Medicine last month.

The post Mustang Bio’s first-of-a-kind CAR-T starts trials appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/mustang-bio-car-t-starts-trials/

0 notes

sapanas · 4 years

Text

Leukemia Therapeutics Market Size, Share, Growth, Forecast, Key Findings, Competitive Landscape, Industry Analysis, Segmentation And Trends

A Broad Analysis of the "Worldwide Leukemia Therapeutics Market “methodology of the leading organizations in the exactness of import/export utilization, market activity figures, cost, value, revenue and gross edges.

Leukemia Therapeutics Market Analysis

Leukemia Therapeutics Market Major Players:

Global Leukemia Therapeutics Market - Competitive Analysis

Global Leukemia Therapeutics Market - Segments

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions: Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

Global Leukemia Therapeutics Market - Regional Analysis

Leukemia Therapeutics Industry/ Innovation/Related News:

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

0 notes

aditi3019 · 4 years

Text

Global Leukemia Therapeutics Market 2019 – 2023: Business Growth Drivers, Emerging Audience, Industry Segments, Global Trends, Profits and Sales

Global Leukemia Therapeutics Market Report, Forecast Period 2023-2020. The Industry Research Report on Global Leukemia Therapeutics Market is based on Industry Size, Share, Trend and Growth.

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/7425

Global Leukemia Therapeutics Market - Segments       

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

Global Leukemia Therapeutics Market - Regional Analysis

Global Leukemia Therapeutics Market - Competitive Analysis

Major Players:

Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). 

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

0 notes